| Literature DB >> 26180817 |
Clare L van Halsema1, Violet N Chihota2, Nicolaas C Gey van Pittius3, Katherine L Fielding1, James J Lewis1, Paul D van Helden3, Gavin J Churchyard4, Alison D Grant1.
Abstract
BACKGROUND: The clinical relevance of nontuberculous mycobacteria (NTM), detected by liquid more than solid culture in sputum specimens from a South African mining workforce, is uncertain. We aimed to describe the current spectrum and relevance of NTM in this population.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26180817 PMCID: PMC4477445 DOI: 10.1155/2015/959107
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Flow chart showing sources of study participants.
Species identified using 16S sequencing, with smear status, HIV status, and CD4 counts (n = 232).
| Species | Number isolated | Number (%) | Number with mixed species4 | HIV prevalence1 (%) | Median CD42 (cells/ |
|---|---|---|---|---|---|
| Clinic patient group | |||||
|
| 25 (26) | 2 (8) | 5 | 8/10 | 87 (14, 827 [5]) |
|
| 21 (22) | 6 (29) | 3 | 5/8 | 85 (39, 763 [5]) |
|
| 9 (9) | 1 (11) | 0 | 3/3 | 102 (66, 138 [2]) |
|
| 9 (9) | 2 (22) | 1 | 1/1 | [0] |
|
| 7 (7) | 0 | 1 | 1/1 | 195 [1] |
| New species | 7 (7) | 1 (14) | 0 | 3/3 | 475 (236, 512 [3]) |
| Other species | 18 (19) | 0 | 2 | 4/5 | 291.5 (154, 492 [4]) |
|
| |||||
| Total | 96 | 12 (12.5) | 12 (12.5% of 96 isolates) | 25/31 (80.6) | 215.5 (14, 827 [20]) |
|
| |||||
| Pre-IPT3 screening group | |||||
|
| 53 (39) | 8 (15) | 5 | 10/12 | 298 (66, 396 [8]) |
|
| 29 (21) | 11 (38) | 1 | 9/14 | 183.5 (69, 544 [8]) |
|
| 13 (10) | 0 | 3 | 4/5 | 211 (92, 534 [4]) |
|
| 12 (9) | 2 (17) | 1 | 1/2 | 223 [1] |
|
| 11 (8) | 0 | 1 | 3/5 | 358 (245, 471 [2]) |
|
| 5 (4) | 0 | 2 | 2/2 | 132.5 (123, 142 [2]) |
| New species | 3 (2) | 0 | 0 | 0/0 | [0] |
| Other species | 10 (7) | 0 | 2 | 3/3 | 311 (252, 370 [2]) |
|
| |||||
| Total | 136 | 21 (15.4) | 15 (11.0% of 136 isolates) | 32/43 (74.4) | 245 (66, 544 [27]) |
1Fisher's exact test for difference in HIV prevalence by species, both groups combined, P = 0.79.
2Median CD4 count by species for those known to be HIV-positive, combining both groups (clinic patients and IPT screening group) and including 8 species compared using Kruskal-Wallis test, which showed no evidence for difference by species, P = 0.42.
3IPT: isoniazid preventive therapy.
4For specimens containing mixed NTM species on PCR sequencing, the main species is reported; minority species were not identified, but the numbers with mixed species are given here. This does not apply to those with concurrent M. tuberculosis, who were excluded from this study.
Species distribution by HIV status, among 74 individuals with known status.
| Species | HIV-positive | HIV-negative |
|---|---|---|
|
| 14 (25) | 8 (47) |
|
| 12 (21) | 3 (18) |
|
| 5 | 1 |
|
| 4 | 1 |
|
| 3 | 1 |
|
| 11 (19) | 2 (12) |
|
| 4 (7) | 2 (12) |
|
| 4 (7) | 1 (6) |
|
| 2 (4) | 0 |
| New species | 3 (5) | 0 |
| Unknown | 7 (12) | 1 (6) |
Symptoms reported by route of recruitment to study and species of nontuberculous mycobacterium isolated (n = 232).
| Species | Number isolated | Number reporting cough | Number reporting night sweats1
| Number reporting haemoptysis | Number reporting weight loss2
| Number reporting fever | Number reporting any symptom | Number with chest radiograph classified as definite or possible active tuberculosis |
|---|---|---|---|---|---|---|---|---|
| Clinic patient group | ||||||||
|
| 25 | 17 (68) | 13 (52) | 4 (16) | 11 (44) | 11 (44) | 19 (76) | 2/14 |
|
| 21 | 11 (52) | 9 (43) | 1 (5) | 10 (48) | 9 (43) | 14 (67) | 4/9 |
|
| 9 | 8 (89) | 7 (78) | 0 | 8 (89) | 6 (67) | 9 (100) | 1/7 |
|
| 9 | 7 (78) | 5 (56) | 0 | 5 (56) | 3 (33) | 7 (78) | 1/5 |
|
| 7 | 5 (71) | 2 (29) | 0 | 4 (57) | 4 (57) | 6 (86) | 1/3 |
| New species | 7 | 5 (71) | 3 (43) | 1 (14) | 2 (29) | 4 (57) | 5 (71) | 0/5 |
| Other species | 18 | 13 (72) | 11 (61) | 3 (17) | 7 (39) | 10 (56) | 15 (83) | 1/7 |
|
| ||||||||
| Total | 96 | 66 (69) | 50 (52.1) | 9 (9.4) | 47 (49.0) | 47 (49.0) | 75 (78.1) | 10/50 |
|
| ||||||||
| Pre-IPT3 screening group | ||||||||
|
| 53 | 26 (49) | 12 (23) | § | 17 (32) | § | 34 (64) | 13/46 |
|
| 29 | 8 (28) | 2 (7.0) | § | 6 (21) | § | 12 (41) | 13/25 |
|
| 13 | 8 (62) | 5 (39) | § | 3 (23) | § | 9 (69) | 1/12 |
|
| 12 | 2 (17) | 2 (17) | § | 4 (33) | § | 6 (50) | 4/11 |
|
| 11 | 5 (46) | 3 (27) | § | 1 (9) | § | 5 (46) | 5/10 |
|
| 5 | 4 (80) | 1 (20) | § | 2 (40) | § | 4 (80) | 2/5 |
| New species | 3 | 1 (33) | 1 (33) | § | 1 (33) | § | 1 (33) | 1/2 |
| Other species | 10 | 5 (50) | 1 (10) | § | 5 (50) | § | 6 (60) | 1/10 |
|
| ||||||||
| Total | 136 | 59 (43.4) | 27 (19.9) | § | 39 (28.7) | § | 77 (56.6) | 40/121 |
1Night sweats were defined by the wording of the question put to study participants: “Do you have drenching night sweats? (Sweat so much at night that clothes/pillows are soaking wet?).”
2Weight loss was defined by the wording of the question put to study participants: “Do you have unintentional weight loss? (In the last 6 months have your clothes become looser?).”
3IPT: isoniazid preventive therapy.
§Data not available as questionnaire used in pre-IPT screening for tuberculosis did not include this question.
Deaths and medical separations, from recruitment until end of 2010, median 32 months (n = 218).
| NTM species | Death | Medical separation | Total number of individuals |
|---|---|---|---|
|
| 0 | 13 (26) | 51 |
|
| 2 (4) | 16 (33) | 49 |
|
| 1 (3) | 12 (32) | 38 |
|
| 2 (11) | 2 (11) | 19 |
|
| 1 (5) | 11 (58) | 19 |
|
| 0 | 1 (20) | 5 |
| New species | 1 (10) | 1 (10) | 10 |
| Other species | 3 (11) | 7 (26) | 27 |
|
| |||
| Total | 10 (4.6) | 63 (28.9) | 218 |
Probability of remaining in the workforce during follow-up for individuals with the three predominant NTM species.
| Species | 6 months | 12 months | 24 months |
|---|---|---|---|
|
| 93.8 (82.0–98.0) | 85.0 (91.0–92.5) | 80.3 (65.5–89.3) |
|
| 87.3 (73.9–94.1) | 78.4 (63.5–87.8) | 69.2 (53.6–80.5) |
|
| 88.3 (71.7–95.4) | 81.7 (63.7–91.4) | 72.9 (52.9–94.4) |
Figure 2Kaplan-Meier graph showing death or medical separation by NTM species isolated for the three most prevalent species (n = 138: 51 M. gordonae; 49 M. kansasii; and 38 M. avium complex).
American Thoracic Society criteria for lung disease due to NTM (adapted from [19]).
| Criteria for diagnosis of lung disease due to NTM | |
|---|---|
| Clinical | (1) Pulmonary symptoms, nodular or cavitary opacities on chest radiograph, or an HRCT scan that shows multifocal bronchiectasis with multiple small nodules |
|
| |
| Microbiological | (1) Positive culture results from at least two separate expectorated sputum samples |